Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
A Casadei-Gardini, Pamela Franco, V. Dell’Acqua, Mario Scartozzi(University of Cagliari), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Giorgia Marisi, Massimiliano Mistrangelo(University of Turin), Stefano Cascinu(Vita-Salute San Raffaele University), Paola Cassoni(University of Turin), D. Aloi, Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), Alberto Argentiero, Salvatore Martini(University of Campania "Luigi Vanvitelli"), Kalliopi Andrikou, Nicola Silvestris(University of Messina), Francesca Montagnani(University of Siena), De Bari B, G. Pugliese, Chiara Casadei, Iorio GC, Prete AA, Francesca Arcadipane, Zampino MG, S Lonardi
DOAJ (DOAJ: Directory of Open Access Journals)
April 1, 2019
Cited by 2
Related Papers
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646